Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance Study for Verquvo (Vericiguat) in Korean Heart Failure Patients With Reduced Ejection Fraction

NCT06148935 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06148935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06148935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance Study for Verquvo (Vericiguat) in Korean Heart Failure Patients With Reduced Ejection Fraction
Lead sponsor
Bayer
Phase
Observational
Overall status
Recruiting
Start date
November 30, 2023
Completion date
October 31, 2027
Enrollment
1,350 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure with reduced ejection fraction